Thanks to an approval from the FDA, people suffering from multiple sclerosis will soon be able to trade in their needles for a pill. Today the FDA approved a new oral drug called Gilenya which treats ...

LONDON (Reuters) - Novartis's multiple sclerosis pill Gilenya, one of its biggest new drug hopes, has been rejected by Britain's healthcare cost-effectiveness watchdog NICE, which judges it not worth ...

ATLANTA — Tests of the first two oral drugs developed for treating multiple sclerosis show that both cut the frequency of relapses and may slow progression of the disease, but with side effects that ...

Next week, a federal advisory panel will consider whether the Food and Drug Administration should approve fingolimod, making it the first pill on the market for the treatment of multiple sclerosis.

LONDON, June 4 (Reuters) - Swiss drugmaker Novartis AG's race to get the first multiple sclerosis pill to market reaches a pivotal point next week when U.S. experts vote on whether Gilenia should be ...

As an FDA advisory panel meets Wednesday to vote on whether to recommend approval of Sanofi’s MS drug Lemtrada, patient opinion leaders have already voiced their view. A small majority told ...

The only approved medications for multiple sclerosis have to be injected into the body, and the worldwide effort to find oral treatments involves researchers at St. Louis University. "A person who is ...

Matthew Herper covers medical innovation — both its promise and its perils. Sanofi said an oral treatment for multiple sclerosis, tolebrutinib, met its key goal in a Phase 3 study, potentially ...

Share on Pinterest Scientists are testing a drug that may offer hope for reversing nerve damage in MS. MANICO/Getty Images Multiple sclerosis (MS) is a chronic disease of the nervous system that can ...

There aren't very many drugs that are also, essentially, industrial chemicals available in railroad-car volumes, pharmaceutical chemist Derek Lowe noted on his blog, In The Pipeline, this spring. But ...

The MS injections have led to pocked skin and other problems so she is leery of new treatments' side effects.The new studies reveal the trade-offs:—A two-year study gave 1,300 MS patients cladribine ...